EVERSANA

Hari Ramachandran unpacks what a fully integrated Direct-to-Patient model really looks like—connecting targeting, outreach, telehealth, prescribing, and home delivery into one seamless experience. Led by a unified commercial team and powered by advanced analytics, our DTP model empowers patients, streamlines access, and drives measurable outcomes. Read the blog: https://ow.ly/qaMG50WXBiS #DTP #PatientCentricity #PharmaInnovation

Many drug launches aren’t meeting revenue goals – but there’s a new strategy on the horizon. What are successful brands doing differently? They’re pairing their integrated commercialization models with the power of a direct-to-patient (DTP) channel. DTPs break through barriers to commercial success by expanding market reach, accelerating access, and improving adherence. Gregory Skalicky, MBA and Penny Bemus share deeper insights on why DTPs are quickly becoming a must in pharma #commercialization. Download the full article: https://ow.ly/Girm50XaNeO #PharmaCommercialization #DirectToPatient #MarketAccess

Since its launch, our AI Agency platform has been making headlines across the industry. In a recent article, PM360 Magazine coined it as "a complete overhaul of the Agency Model.” Check out what it has to offer here: https://lnkd.in/eZeX55DF #PharmatizingAI #HealthcareMarketing #FutureOfPharma

We’re proud to collaborate with global leaders in rare disease innovation during a powerful session led by Chiesi Global Rare Diseases. We’re especially honored to work with Dr. Maurizio Scarpa whose leadership at MetabERN is shaping the future of digitally-enhanced rare disease care across Europe and to support with our health innovation expertise led by Alberta Spreafico, PhD, MBA and Pierantonio Russo MD, FCPP, FAAP, STS. See us at #WODCEU2025: “Enabling Digitally-Enhanced Care for Rare Diseases in Europe” ️| October 27, 2026 @ 14:00 CET https://ow.ly/3PO150X6af7 Featuring: • Enrico Piccinini, SVP EU & International at Chiesi Global Rare Diseases and Chair of the Farmindustria National Working Group on Rare Diseases in Italy • Alberta Spreafico, SVP Health Innovation, EVERSANA; Adjunct Professor, University of Pavia; Academic Fellow Government, Health and Not for Profit Division, SDA Bocconi School of Management. • Dr. Maurizio Scarpa, European Coordinator of MetabERN and Director of the Regional Coordinator Centre for Rare Diseases at the University Hospital of Udine in Italy • V.P. Andriukaitis, EU Member, Member of ENVI; Coordinator of SANT; Substitute member of AFCO; Member of the Group of the Progressive Alliance of Socialists and Democrats in the European Parliament • Dr. Pierantonio Russo, Corporate Chief Medical Officer EVERSANA, Principle Investigator Special NIH Project for the Diagnosis of RD • Kim Angel, Executive Director of International MPS Network • Dr. Monica Otto, Associate Professor of Practice and Director for Executive Education Programs for Health and Social Care at SDA Bocconi School of Management #RareDiseases #DigitalHealth #Chiesi #MetabERN #Innovation #Collaboration

Citius Oncology, Inc. has signed an exclusive commercialization agreement with EVERSANA to support the planned Q4 2025 launch of LYMPHIR™ Read more here: https://lnkd.in/gWfXcXDg #OncologyExcellence #Commercialization

Heading to #BIOEurope and looking for partnership options for your asset? EVERSANA makes it easy! Whether you’re aiming to commercialize or build value for a sale or licensing deal, we’ve got you covered. With a flexible, ready-to-use commercial infrastructure and a team of experts, we’ve signed more than 20 partnerships in the last three years. Our model reduces financial risks and optimizes resources for successful product launches. Let’s connect at BIO in Vienna to discuss how we can work together! Send your appointment request: https://ow.ly/EQij50WQqfZ #Partnerships #Commercialization

📈 Making Market Access Measurable with NAVLIN Insights KPI Discover how a global oncology leader transformed fragmented pricing data into a centralized KPI platform—unlocking real-time insights, faster decisions, and stronger strategic alignment across teams. - Centralized dashboards - Fast wins, long-term impact - KPI framework now shaping boardroom conversations 💡 From data to decisions—this is how launch excellence is done. 👉 Download the full case study: https://ow.ly/WUfc50X2al9 #MarketAccess #PharmaLaunch #EVERSANA #NAVLIN #Pricing #LifeSciences #KPI #DataDrivenStrategy #LaunchExcellence NAVLIN by EVERSANA Marian Monchais Charlotte Palumbo

Connect with experts from EVERSANA’s Donor Eligibility System at American Society for Reproductive Medicine - ASRM 2025! Stop by booth 949 to learn more about how we’re advancing operations and accelerating compliance through our automated, web-accessible platform that assists in the donor eligibility determination process. https://ow.ly/2QKz50WZ8xP #ASRM2025 #DonorEligibility #ComplianceSolutions

What happens when tech meets purpose? Mike Ryan sees Frontiers Health as a space to rethink how innovation can drive better access and outcomes across healthcare. Be part of the conversation and hear Mike’s main stage session on the Brave New Commercialization World, this November 11-12 in Berlin https://lnkd.in/dNN4MMd #FH25 #HealthInnovation #DigitalHealth

Creative brewed faster than your morning cup of coffee? Yes, really. Marketing assets that once took weeks or months to deliver are now being created in seconds with compliance and quality! Our AI Agency Platform – built in partnership with Google – is revolutionizing pharma marketing with unmatched speed and precision. Request a Demo: https://lnkd.in/eZeX55DF #PharmaMarketing #AIAgency #PharmaInnovation #AIinPharma